Frequency News and Research

RSS

Survey of American children's oral health released

While a majority of Americans rate their children's oral health as "excellent," there are clear gaps in understanding of basic oral health procedures and actual behavior.

15 Sep 2009

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

Pharmos Corporation (Pink Sheets: PARS) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.

14 Sep 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they have formed a partnership to provide education to physicians and liver patients about the treatment options for hepatocellular carcinoma (commonly referred to as primary liver cancer) and Celsion’s on-going ThermoDox Phase III global HEAT clinical study.

14 Sep 2009

Patni Computer to provide design and development services to Cardiac Science Corporation

Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, announced a three-year agreement with Patni Computer Systems under which Patni will establish a dedicated design center in India and will expand Cardiac Science's existing in-house design and development capability.

14 Sep 2009

AVONEX results in fewer injection site reactions, according to a clinical study

Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon- (interferon beta-1b), Copaxone- (glatiramer Acetate) or Rebif - (interferon beta-1a).

13 Sep 2009

University of Surrey lecturer on Co-sleeping

The event will be a series of overlapping presentations based on video clips of older people talking about their experience of poor sleep, and the impact this has on their lives. The presenters are all involved in the SomnIA (Sleep in Ageing) project based at the University of Surrey. As well as the video-based presentations and discussions, members of the audience will be invited to share some of their own experiences of poor sleep, and write down questions which they would like the panel of presenters to address during the last part of the event.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Phase 3 trial of ataluren commences

PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).

11 Sep 2009

Cisco deploys Integrated Medical-Grade Network at HIAE

Cisco today announced the deployment of an Integrated Medical-Grade Network at the Albert Einstein Israeli Hospital (HIAE) in Sao Paulo city. The Hospital is recognized in Latin America for pioneering the innovative use of technology to streamline business processes and deliver value to its patients.

11 Sep 2009

New Mobile Cardiac Outpatient Telemetry system from CardioNet

CardioNet, Inc. today announced the availability of new, innovative clinical and reporting enhancements to the Company’s existing Mobile Cardiac Outpatient Telemetry™ (MCOT™) service.

11 Sep 2009

New study reveals that actual sex ratios can sway from the ideal

In a perfect world, for every boy there would of course be a girl, but a new study shows that actual sex ratios can sometimes sway very far from that ideal. In fact, the male-to-female ratio of one tropical butterfly has shifted rapidly over time and space, driven by a parasite that specifically kills males of the species, reveals a report published online on September 10th in Current Biology, a Cell Press publication.

11 Sep 2009

Regular usage of CGM devices help manage diabetes

The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.

9 Sep 2009

Individuals with upper-GI symptoms visit general practitioners often

Patients with upper gastrointestinal (GI) complaints visit their general practitioner (GP) more often than patients with other conditions. Researchers writing in the open access journal BMC Family Practice found that people with dyspepsia, heartburn, epigastric discomfort and other upper-abdominal complaints had almost twice as many GP contacts, which were ultimately associated with problems in all organ systems.

9 Sep 2009

Haemonetics acquires SEBRA's blood collection and processing business

Haemonetics Corporation, a global blood management solutions company, and Engineering and Research Associates Inc. (known as "SEBRA(R)"), a leading provider of blood and medical manufacturing technologies, announced today that Haemonetics has acquired the assets of SEBRA's blood collection and processing business for $12.5 million cash. The acquisition is expected to close within the next several weeks.

8 Sep 2009

Chronic pediatric cough linked to reflux and allergies

New research shows that chronic cough in children is most often caused by gastroesophageal reflux and allergies. Researchers from Tulane University in New Orleans, LA, evaluated 40 patients aged 5 to 12 years with chronic cough (> 8 weeks in duration) with no obvious cause. Each patient underwent extensive multispecialty testing. Results showed that reflux was the single most commonly associated factor of chronic cough by itself (27.5 percent), followed by allergy (22.5 percent).

8 Sep 2009

Oxidative DNA damage: Primary cause of mutation

A study that tracked genetic mutations through the human equivalent of about 5,000 years has demonstrated for the first time that oxidative DNA damage is a primary cause of the process of mutation - the fuel for evolution but also a leading cause of aging, cancer and other diseases.

8 Sep 2009

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

The 2009 Heart and Stroke Foundation Report on health of Ontario's kids

In 1998, the Heart and Stroke Foundation's Report Card on Canada's Kids took a hard look at the heart health of Canadian children aged 6-12. More than 10 years later, the Foundation shines the spotlight on Ontario's kids - and will be issuing its own Report Card on the heart health of this young cohort.

4 Sep 2009

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.

3 Sep 2009